Gallbladder problems are among the more consistently documented risks associated with GLP-1 medications, appearing in the FDA labeling for semaglutide, liraglutide, and tirzepatide alike. Unlike some safety signals that remain uncertain, this one has a reasonably well-understood mechanism behind it.
Why GLP-1 Drugs Raise Gallbladder Risk
Two separate mechanisms appear to contribute. First, rapid, substantial weight loss is itself an independent, well-established risk factor for gallstone formation, regardless of how the weight loss is achieved; it alters the composition of bile and increases the concentration of cholesterol relative to the bile salts that normally keep it dissolved. Second, GLP-1 receptor agonists slow gastrointestinal motility as part of their core mechanism, including gallbladder emptying, and a gallbladder that empties less frequently and less completely is more prone to forming stones and sludge.
What the Trial Data Show
Pooled analyses of semaglutide's clinical trial program, including the SUSTAIN and STEP trial series, have found an increased relative risk of gallbladder-related adverse events, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), compared with placebo. The magnitude varies by analysis and dose, but several pooled estimates have put the relative risk increase in roughly the range of 1.5 to 3 times that of placebo, with higher risk generally associated with higher doses and faster, larger amounts of weight loss. Tirzepatide's trial program has shown a similar pattern of increased gallbladder-related events relative to placebo, consistent with the shared weight-loss and motility mechanisms. Liraglutide's earlier approval studies showed the same signal, which is part of why gallbladder-related risk is now addressed across the GLP-1 drug class's labeling rather than treated as a single drug's quirk.
Who Appears to Be at Higher Risk
Within these trials, people who lost weight fastest and in the greatest amounts tended to show the highest gallbladder-related event rates, suggesting the rate of weight loss itself, not just the drug class, is a meaningful variable. People with pre-existing gallstones, a prior history of gallbladder disease, or other independent gallstone risk factors, such as obesity itself, female sex, or rapid weight cycling, may be at further elevated risk, though GLP-1-specific research breaking down risk by these subgroups in detail remains more limited than the overall trial signal.
Warning Signs to Know
Symptoms of a gallbladder problem that warrant prompt medical attention include persistent or severe pain in the upper right abdomen, pain that spreads to the back or right shoulder, fever, nausea or vomiting that doesn't resolve, and yellowing of the skin or eyes (jaundice), which can indicate a blocked bile duct. These symptoms should not be dismissed as routine GLP-1 side effects like nausea, since they can indicate a complication requiring prompt evaluation, including gallbladder removal in some cases.
The Bottom Line
Gallbladder disease is a documented, labeled risk of GLP-1 medications with a reasonably clear biological explanation, not a rare or speculative signal. It does not mean everyone taking these drugs will develop gallstones, but it is a real enough risk that anyone starting a GLP-1 medication, especially at higher doses or with a prior gallbladder history, should know the warning signs and discuss their individual risk with a physician before starting treatment.